Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades NeuBase Therapeutics to Perform

Oppenheimer Downgrades NeuBase Therapeutics to Perform

Oppenheimer analyst Hartaj Singh downgrades NeuBase Therapeutics (NASDAQ:NBSE) from Outperform to Perform.

byBenzinga Newsdesk

October 21, 2022

1 minute read

Oppenheimer analyst Hartaj Singh downgrades NeuBase Therapeutics (NASDAQ:NBSE) from Outperform to Perform.

$1.7 Million Bet On This Biotechnology Stock? 3 Penny Stocks Insiders Are Buying

By Lisa Levin

July 19, 8:05 AM

U.S. stock futures traded higher this morning after recording losses in the previous session. Investors, meanwhile, focused on some notable insider trades.

EPIX

What’s Going On With Carvana Stock?

By Adam Eckert

October 12, 11:59 AM

Carvana Co (NYSE: CVNA) shares are trading lower Thursday following bearish analyst coverage.

CVNA

Truist Securities Upgrades Comcast to Buy, Announces $50 Price Target

By Benzinga Newsdesk

January 5, 8:20 AM

Truist Securities analyst Greg Miller upgrades Comcast (NASDAQ:CMCSA) from Hold to Buy and announces $50 price target.

CMCSA

These Analysts Cut Their Forecasts On Crown Castle Following Q1 Results

By Priya Nigam

April 18, 9:30 AM

Crown Castle Inc. (NYSE: CCI) reported upbeat first-quarter sales results on Wednesday.

CCI

Oppenheimer Downgrades NeuBase Therapeutics to Perform

Related Posts

$1.7 Million Bet On This Biotechnology Stock? 3 Penny Stocks Insiders Are Buying

What’s Going On With Carvana Stock?

Truist Securities Upgrades Comcast to Buy, Announces $50 Price Target

These Analysts Cut Their Forecasts On Crown Castle Following Q1 Results